New analysis of the current clinical trial landscape in the UK shows clear opportunities to shape the future of medical research and patient care. The ...

The World Health Organization (WHO) has confirmed the successful redesignation of the Medicines and Healthcare products ...

The MHRA has approved eplontersen (Wainzua) for treating adults with polyneuropathy associated with hereditary transthyretin ...

Trofolastat is a prostate-specific membrane antigen-targeting agent cleared for use with Technetium-99m for cancerous lesion ...

On March 17, 2025, the government published a policy paper with an Action Plan for regulation and regulators, outlining how it intends to reform ...

UK MHRA approves eplontersen to treat adults with rare inherited nerve disease or polyneuropathy: United Kingdom Monday, April 7, 2025, 15:00 Hrs [IST] The Medicines and Healthcar ...

A new study from Queen Mary University of London found that 9% of all reported adverse drug reactions (ADRs) reported to the ...

PLC (AIM: 4BB) (“4basebio”), a company which develops and commercializes the large-scale manufacture of synthetic DNA as well as nanoparticle delivery solutions, today announced that it has received ...

The MHRA has approved trofolastat to identify how far high-risk prostate cancer has spread before treatment, to detect ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved trofolastat (RoTecPSMA), the first prostate-specific membrane antigen (PSMA)-targeting product authorised for use with ...

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval for trofolastat (RoTecPSMA), a prostate-specific membrane antigen (PSMA)-targeting agent for detecting ...